Microtest to manufacture ImmusanT's celiac vaccine

Microtest Laboratories will manufacture Nexvax2 for a mid-stage trial of ImmusanT's vaccine as a treatment for celiac disease. ImmunsanT secured $20 million in venture captial funding from Vatera Healthcare Partners in December to advance clinical development of the vaccine. Article

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.